← All trials
NCT00000491
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 1974
- Primary completion
- —
- Completion date
- Aug 1, 1979
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- St. Joseph Hospital Health CenterOfficial
- University of California, DavisOfficial
- University of CincinnatiOfficial
- University of MiamiOfficial
- Northwestern UniversityOfficial
- University of WashingtonOfficial
- University of Southern CaliforniaOfficial
- Virginia Commonwealth UniversityOfficial
- Emory UniversityOfficial
- University of MichiganOfficial
- Rush UniversityOfficial
- Salt Lake Clinic Research FoundationOfficial
- Santa Rosa Medical CenterOfficial
- Lankenau HospitalOfficial
- Palo Alto Medical Research FoundationOfficial
- Pacific Health Research InstituteOfficial
- Rutgers UniversityOfficial
- Greater Baltimore Medical CenterOfficial
- Boston Health and Hospitals DepartmentOfficial
- Ogden Research FoundationOfficial
- University of Puerto RicoOfficial
- Cornell UniversityOfficial
- University of MarylandOfficial
- Northwell HealthOfficial
- George Washington UniversityOfficial
- Henry Ford Health SystemOfficial
- University of MississippiOfficial
- Centers for Disease Control and Prevention (CDC)Official
- Icahn School of Medicine at Mount SinaiOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.